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Abstract
Purpose—Pluronic block copolymers are potent sensitizers of multi-drug resistant (MDR) cancer
cells. The sensitization effect by Pluronics is a result of two processes acting in concert: i) intracellular
ATP depletion, and ii) inhibition of ATPase activity of drug efflux proteins. This work characterizes
effects of Pluronic P85 on ATPase activities of Pgp, MRP1, and MRP2 drug efflux transport proteins
and interaction of these proteins with their substrates, vinblastine, and leucotriene C4.
Methods—Using membranes overexpressing Pgp, MRP1, and MRP2, the current study evaluates
effects of Pluronic P85 (P85) on the kinetic parameters (Vmax, Km, Vmax/Km) of ATP hydrolysis by
these ATPases.
Results—The decreases in the maximal reaction rates (Vmax) and increases in apparent Michaelis
constants (Km) for these transporters in the presence of various concentrations of P85 were observed.
The mechanism of these effects may involve i) conformational changes of the transporter due to
membrane fluidization and/or ii) nonspecific steric hindrance of the drug-binding sites by P85 chains
embedded into cellular membranes. The extent of these alterations was increased in the row MRP1
< MRP2 << Pgp.
Conclusions—These data suggest that there are unifying pathways for the inhibition of Pgp and
MRPs by the block copolymer. However, the effect of P85 on Pgp ATPase activity is considerably
greater compared with the effects on MRP1 and MRP2 ATPases. This may be a reason for greater
inhibitory effects of Pluronic in Pgp- compared with MRP-overexpressing cells.
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INTRODUCTION
Intrinsic or acquired resistance of malignant tumors to chemotherapeutic agents drastically
decreases the outcomes of chemotherapy of cancer (1–3). Therefore, discovery and
development of agents that are able to reverse resistance of malignancies is necessary to
improve the therapeutic out-comes. One major cause of drug resistance is an increase in the
activity or amount of drug efflux transport proteins, which are able to extrude xenobiotics out
of the tumor cells. The chemical nature of the substrates handled by these proteins is extremely
diverse; from inorganic ions to sugars and large polypeptides. The efflux proteins implicated
in drug resistance include P-glycoprotein (Pgp) and multidrug resistant proteins (MRP), which
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belong to a superfamily of ABC transporters (4,5). Intensive laboratory and clinical studies to
over-come drug resistance in cancer use inhibitors or reversal agents for these proteins (6–8).
Pluronic block copolymers is a new class of efficient inhibitors of Pgp that were shown to
increase accumulation and cytotoxicity of many drugs in Pgp-overexpressing cell lines (9,
10). One Pluronic-based formulation of doxorubicin is currently evaluated in clinical trials for
treatment of MDR tumors (11). Laboratory studies have shown that Pluronics sensitize Pgp-
overexpressing cells resulting in an increase in the cytotoxic activity of anthracyclines and
other anticancer drugs by as much as 2 to 3 orders of magnitude (9,12). Studies of the
mechanism of sensitization effects by P85 suggested an essential role of ATP depletion in
MDR tumors (10,13). Furthermore, it was shown that P85 molecules rapidly adhere to the cell
membranes and incorporate into them. This alters the structure of the lipid bilayers
accompanied by significant decreases in Pgp ATPase activity (14,15). The combination of 1)
ATP depletion and 2) inhibition of ATPase activity is necessary for effective inhibition of Pgp
(13–15). These findings are of importance considering that Pgp and MRPs are members of the
“traffic ATPase” superfamily (4,5), which use the energy of ATP hydrolysis for maintaining
their membrane transport function. However, several studies suggested that Pluronics have
much weaker, if any, effect on MRPs compared with Pgp (15–17). The ATP depletion induced
by Pluronic has been reported in MRP-overexpressing cells (15). Therefore, we posit that
differences in the effects of Pluronic on Pgp and MRP involve different effects of these
copolymers on the ATPase activity of the transporters. To test this hypothesis we characterized
the effects of Pluronic P85 (P85) on drug efflux transporters by assessing kinetic parameters
for ATP hydrolysis in Pgp-, MRP1-, and MRP2-overexpressing membranes. Along with the
protein-ATP interactions, the kinetic studies examined the effects of P85 on binding of the
drugs (vinblastine and leucotriene C4) and determined to what extent the block copolymer can
interfere with the ability of these drugs to specifically activate the ATPase. Overall, the study
provides insight into the mechanism of Pluronic sensitization effects in the MDR cancer cells




Pgp-overexpressing membranes were purchased from Gentest Co. (Woburn, MA, USA).
Crude plasma membranes fraction overexpressing MRP1 or MRP2 was isolated from COR-
L23/R or MDCKII-MRP2 cells respectively as described earlier (15). Pluronic P85 was a gift
from BASF Co. (Parispany, NJ, USA). P85 solution in phosphate buffered saline (PBS), 20%
(w/v), was used in these studies. All concentrations of P85 solutions are presented in % (w/v).
Acridone carboxamide derivative, GF120918, was kindly provided by Dr. Kenneth Brouwer
(Glaxo Wellcome, Inc., Research Triangle Park, NC, USA). Vinblastine (Vin), leucotriene
C4 (LTC4), Mg2+ATP, and all other chemicals were purchased from Sigma Chemical Co. (St.
Louis, MO, USA).
Cells
The porcine kidney epithelial cell line, LLC-MDR1, derived by transfection with human
MDR1 in the laboratory of Dr. Piet Borst (The Netherlands Cancer Institute, Amsterdam, The
Netherlands), were obtained from Dr. Erin Schuetz (St. Jude Hospital, Memphis, TN, USA).
The cells were cultured in Medium 199 with 10% FBS, 10 mM HEPES, and penicillin/
streptomycin. LLC-MDR1 cultures were supplemented with 640 nmol/ml vincristine (SP
Pharmaceuticals Inc, Albuquerque NM, USA). The MRP2-transfected Madin Darby Canine
Kidney (MDCK) cells, MDCKII-MRP2, were also gift from Dr. Piet Borst. Cells were
maintained in Dulbecco’s modified Eagle’s medium (DMEM), containing 10% heat-
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inactivated fetal bovine serum (FBS) and 50 U/ml penicillin/streptomycin. Human lung
carcinoma epithelial cells, COR-L23/R, were purchased from European Collection of Cell
Cultures. The cells were maintained in RPMI 1640 medium with 2 mM glutamine, 0.2 μg/ml
doxorubicin (for COR-L23/R), and 10% FBS. Tissue culture media were obtained from Gibco
Life Technologies, Inc. (Grand Island, NY, USA). Serum and medium supplements were
purchased from Sigma Chemical Co. (St. Louis, MO, USA).
Western Blot Analysis
Identification of Pgp, MRP1, and MRP2 was done using immunoblot technique described
previously (18). To avoid cross-staining of the protein bands, three suspensions of the
membranes overexpressing Pgp, MRP1, and MRP2 were loaded in three different gels, and
following transfer each blot was stained with one type of antibodies, against Pgp, MRP1, or
MRP2. The monoclonal antibodies to Pgp, C219 (Dako Corp., Carpinteria, CA, USA), MRP1,
MRPm6 (Kamiya Biomedical Corp., Seattle, WA, USA), and MRP2, M2III-6 (Alexis Corp.,
San Diego, CA, USA), were used at 1:100 dilutions. The monoclonal antibodies to β-actin,
anti-β-1-chicken Integrin (Sigma Corp., St. Louis, MO, USA) were used at 1:200 dilution. The
secondary horseradish peroxide anti-mouse Ig antibodies (1:1500 dilution) were purchased
from Amersham Life Sciences (Cleveland, OH, USA). To correct for loading differences, the
levels of proteins were normalized to constitutively expressed β-actin.
Pgp ATPase Assay
Kinetic effects of P85 on Pgp ATPase activity were evaluated using suspension of Pgp-
overexpressing membranes purchased from Gentest Co. (Woburn, MA, USA). The Pgp
ATPase activity assay was performed as described earlier (14). Briefly, a mixture of Pgp-
overexpressing membranes with or without P85 was added to various concentrations
Mg2+ATP solutions and incubated at 37°C for 20 min. An identical reaction mixture containing
100 μM sodium orthovanadate was assayed in parallel. Orthovanadate inhibits Pgp by trapping
Mg2+ADP in the nucleotide-binding site. Thus, ATPase activity measured in the presence of
orthovanadate represents non-Pgp ATPase activity and can be subtracted from the total activity
measured in the various samples to yield Pgp ATPase activity. The reaction was stopped by
the addition of 10% SDS and liberation of inorganic phosphate was detected by colorimetric
reaction with ascorbic acid in ammonium molybdate solution according to (19). To examine
the effects of P85 on the protein-drug interactions various concentrations of Pgp substrate, Vin,
were added to the mixture of Pgp membranes and Mg2+ATP followed by Pgp ATPase assay
performed as described above.
MRP1 and MRP2 ATPase Assay
Effects of P85 on MRP1 and MRP2 efflux were determined using plasma membrane fractions
isolated from MRP1-overexpressing COR-L23/R or MRP2-transfected MDCKII-MRP2 cells.
Expression of high amounts of MRP1 or MRP2 in these membranes and low amounts of Pgp
was shown previously by Western Blot technique (15). Orthovanadate, known as an inhibitor
of MRPs ATPase activity (20), was added to a half of the membranes to determine non-MRPs
ATPase activity. Values of non-MRPs ATPase activity were subtracted from total ATPase
activity to obtain specific MRPs ATPase activity. Similar to Pgp ATPase activity studies values
of MRPs ATPase activity were determined with or without P85.
Calculations
Values of Pgp and MRPs ATPase activity were obtained over the range of ATP concentrations.
The data were plotted using double reciprocal plots according to Lineweaver and Burk (21) to
determine maximal reaction rates (Vmax), and apparent Michaelis constants (Km) for ATP
hydrolysis by Pgp or MRPs. Km and Vmax parameters for the protein-drug binding were
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determined under the pseudo first-order reaction conditions with fixed concentration of ATP
(4 mM or 12 mM), and over the range of Vin or LTC4 concentrations. The entire curve fitting
was carried out using GraphPad Prism 3.0 (GraphPad software, San Diego, CA, USA).
3H-P85 Accumulation Studies
A tritium label was incorporated into P85 by treatment of the copolymer film with atomic
tritium as previously described (22). The sample of 3H-P85 with specific activity of 0.3 Ci/
mmol was obtained. This sample was further diluted in the assay buffer to obtain 0.5 μCi/ml
(1.6 nM) 3H-P85. The kinetic of 3H-P85 accumulation was examined in confluent LLC-MDR1,
COR-L23/R, or MDCK-MRP2 monolayers at 37°C. To evaluate possible effects of Pgp or
MRP efflux on 3H-P85 transport, GF120918 (inhibitor of Pgp efflux system), or indomethacin
(inhibitor of MRP efflux system) were used in the experiments with Pgp- or MRPs-
overexpressing cells respectively. After 30 min pre-incubation period in assay buffer, or in 1
μM GF120918 (in case of LLC-MDR1), or in 10 μM indomethacin (in case of COR-L23/R
and MDCK-MRP2) solutions, the cell monolayers were exposed to 3H-P85 in the presence of
corresponded inhibitor solution or without it for various time intervals. Then, the treatment
solutions were removed and cells were washed with ice-cold PBS. The cell monolayers were
solubilized in 1% Triton X-100 (0.5 ml) and aliquots were taken for subsequent determination
of radioactivity (Tricarb 4000, Packard, Meriden, CT, USA). All experiments were conducted
in quadruplicate. Values for cellular accumulation of 3H-P85 were normalized for cellular
protein content. Protein concentrations were determined using the Pierce (Rockford, IL, USA)
bicinchoninic acid method.
3H-P85 Transport Studies
Polycarbonate membrane inserts with confluent LLC-MDR1, or MDCK-MRP2 cell
monolayers were placed in Side-Bi-Side diffusion cells from Crown Bio Scientific, Inc.
(Somerville, NJ, USA) maintained at 37°C. Trans-epithelial electrical resistance (TEER)
values were recorded as indexes of cell viability and monolayer integrity. Under basal
conditions, mean resistance was 250 ± 19.8 Ω · cm2 and 185.0 ± 16.7 Ω · cm2 for LLC-MDR1
and MDCK-MRP2, respectively. Cell monolayers were pre-incubated for 30 min at 37°C with
the assay buffer added to both, donor and receiver chambers, or 1 μM GF120918 (for LLC-
MDR1), or 10 μM indomethacin (for MDCK-MRP2). Transport of 3H-P85 in assay buffer or
in 1 μM GF120918 across Pgp-transfected cell monolayers from AP to BL as well as from BL
to AP direction was studied as described elsewhere (14). Similarly, transport of 3H-P85 in
assay buffer, or in 10 μM indomethacin was performed across MRP2-transfected cell
monolayers. The amount of 3H-P85 transported across the monolayers was determined using
a Tricarb 4000 (Packard, Meriden, CT, USA). All transport experiments were conducted at
37°C and in triplicate.
Statistical Analysis
All statistical tests were performed by GraphPad Prism 3.0 (GraphPad software, San Diego,
CA, USA) using the two-tailed heteroscedastic t tests. A minimum p value of 0.05 was
estimated as the significance level for the all tests.
RESULTS
Expression of Efflux Proteins in the Cellular Membranes
The levels of the expression of the drug efflux proteins in the cellular membranes were
determined using Western blot analysis (Fig. 1). Significant amounts of the drug efflux proteins
were found as follows: Pgp in Pgp membranes (line 1), MRP1 in MRP1 membranes (line 2),
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and MRP2 in MRP2 membranes (line 3). There was little, if any, expression of other tested
proteins in each of the membrane samples.
Effects of P85 on ATP Hydrolysis by Pgp
The rates of ATP hydrolysis in Pgp membranes in the presence of P85 were determined and
plotted as a function of a substrate (Mg2+ATP) concentration (Fig. 2A). As is seen in the figure,
0.01% P85 as well as 1% P85 did not affect the maximal rate of ATP hydrolysis (Vmax). In
contrast, 0.1% solution of block copolymer significantly decreased Vmax. Using the double
reciprocal Lineweaverer-Burk plot (Fig. 2B) we obtained kinetic parameters, Vmax and Km, for
this reaction (Table I). Km values were increased in the presence of P85 indicating that the
block copolymer decreases affinity of Pgp to ATP. The concentration dependence of Pluronic
effect was unusual. Significant changes in Km values were observed at relatively low
concentrations of P85. Thus, addition of 0.01% P85 resulted in the increase of Km value about
10-fold. As the concentration of P85 was increased, the magnitude of its effect was diminished.
In particular, 1% P85 practically did not affect the kinetic parameters. The Vmax/Km ratio
displayed similar pattern as the Km value, suggesting the strongest inhibition effect on Pgp
ATPase at a relatively low concentration of P85 (0.01%).
Effects of P85 on Pgp-Drug Interaction
A Pgp substrate, Vin, was used to evaluate the effects of P85 on Pgp-drug specific interactions.
Vin is known to increase Pgp ATPase activity (23). Therefore, alterations in Pgp ATPase
activity caused by P85 in the presence of Vin should reflect changes in Pgp-Vin interaction
induced by the copolymer. Based on the results of the previous experiment, we used 0.01%
and 0.1% P85. The experiment was carried out in the presence of 4mM Mg2+ATP, i.e., non-
saturating ATP concentration (as follows from the Fig. 2A). The results of the experiment are
shown on Fig. 3. As is seen in the figure, P85 inhibited the drug-stimulated ATPase activity
in a concentration-depended manner: the more the block copolymer was added, the higher the
inhibition effect was. Table II presents kinetic constants for this process. For example, 0.1%
P85 decreased Vmax and increased Km by 4.5 and 50 times respectively resulting in overall
decrease in the Vmax/Km value by about 230-fold. Moreover, when high concentration of ATP
(12 mM) was used in the treatment solutions (ATP-saturated conditions) P85 also inhibited
ATPase activity inducing about 120-fold decrease in Vmax/Km ratio (Table II).
Effects of P85 on ATP Hydrolysis by MRP1 and MRP2
The rates of ATP hydrolysis in MRP1 and MRP2 membranes were obtained and plotted vs.
Mg2+ATP concentrations (Figs. 4A and 5A, respectively). As is seen in Fig. 4A, 0.1% P85
caused relatively subtle (but statistically significant) inhibition effect on MRP1. In this case
Vmax was decreased by about 1.3 fold, although Km did not change (Table III). The effect of
0.1% P85 on ATP hydrolysis by MRP2 membranes was more pronounced than in the case of
MRP1 (Fig. 5A). The Vmax was slightly decreased, and Km was increased, which resulted in
2.4 fold decrease in Vmax/Km ratio (Table III).
Effects of P85 on MRP1 and MRP2 Interactions with Drugs
This study initially used a Pgp substrate, Vin, which is also known to interact with MRP1 and
MRP2. Figures 4B and 5B show MRP1 and MRP2 ATPase activities in the presence of Vin
with and without 0.1% P85, and Table IV summarizes the kinetic parameters. The block
copolymer significantly altered the kinetic parameters of MRP-drug interactions. Specifically,
Vmax was decreased, and Km was increased resulting in overall decrease of Vmax/Km ratio by
about 14 times for MRP1 and 6 times for MRP2-overexpressing membranes (Table IV).
Because Vin is not an ideal substrate for MRPs we also evaluated the effect of P85 on
interactions of MRP1 and LTC4, a high affinity substrate for MRP1 and MRP2 (24,25). As is
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seen in Table IV, 0.1% P85 considerably altered the kinetics constants resulting in overall 6-
fold decrease in Vmax/Km ratio.
3H-P85 Accumulation and Transport Studies
To evaluate whether P85 is a substrate for the efflux proteins the kinetic of 3H-P85
accumulation in cells overexpressing Pgp, MRP1, and MRP2 was examined in the presence
of Pgp and MRPs inhibitors, respectively. Specifically, 1 μM GF120918, a Pgp inhibitor
(16), and 10 μM indomethacin, a MRPs inhibitor (26), were used in these experiments. Figure
6 shows the kinetics of 3H-P85 accumulation in Pgp- and MRP2-overexpressing cells, LLC-
MDR1 and MDCKII-MRP2. As is seen in figure, accumulation levels of 3H-P85 were not
altered in the presence of the inhibitors. To reinforce this result we also studied the effect of
GF120918 and indomethacin on 3H-P85 transport across polarized LLC-MDR1 and MDCK-
MRP2 monolayers. The transport of the block copolymer was performed in both, apical to
basolateral and basolateral to apical directions. No differences in the kinetics of 3H-P85
transport in either direction were found (data not shown) indicating that P85 is not a substrate
for these transporters.
DISCUSSION
Previous studies demonstrated that P85 1) decreases intracellular ATP levels (energy depletion)
and 2) increases membrane fluidity resulting in inhibition of ATPase activity of Pgp in
multidrug resistant cells (13,14). These two effects combined are essential for inhibition of
Pgp drug efflux system and chemosensitization of these cells. Furthermore, P85 treatment also
resulted in ATP depletion in MRP1- and MRP2-overexpressing cells (15). However, the effects
of P85 on MRP efflux systems in these cells are substantially less compared to the effects on
Pgp. We hypothesized that the difference in the potency of P85 with respect to Pgp and MRPs
is due to the different ability of the block copolymer to alter ATPase activity of these
transporters. Therefore, we examined the effects of P85 on ATPase activity using isolated Pgp-,
MRP1-, and MRP2-overexpressing membranes.
The Km values obtained in this work in Pgp membranes, 0.4 ± 0.08 mM (ATP) and 0.63 ± 0.15
μM (Vin) are in a good agreement with the values reported before: 0.3-0.4 mM (ATP) and 0.5–
1.5 μM (Vin) (27–29). Somewhat higher Km (7 μM) was reported for Vin in Pgp-expressing
living cells (30). A broad range of Km values for ATP was reported in MRP1 membranes: 3
mM (31), 0.1 mM (32), and 0.023 mM (33). Our measurements for MRP1 membranes suggest
Km of 0.43 ± 0.08 mM. The Km for Vin in MRP1 membranes was not available in the literature
to compare with our data (5.2 ± 0.7 μM). The Km values for MRP2 membranes obtained in this
work, 0.3 ± 0.05 mM (ATP) and 3.3 ± 0.7 μM (Vin), were relatively close to those reported
earlier: 0.56 mM (ATP) (34) and 1.5 ± 0.3 μM (Vin) (35). Finally our Km for LTC4 in MRP1
membranes (0.077 ± 0.12 μM) was also in good agreement with earlier reports: 0.07 to 0.12
μM (24,25).
Addition of P85 resulted in substantial decrease in Vmax and increase in Km values in Pgp
membranes. The concentration dependence of P85 effects on Pgp was unusual; the block
copolymer was most effective at relatively low concentrations. As the concentration of P85
was increased its effect was diminished. Furthermore, the maximal effect of P85 on Vmax was
observed at higher concentration of the block copolymer (0.1%) than the effect on Km (0.01%).
The Vmax/Km ratio, which characterizes the efficiency of the enzymatic reaction at resting
concentrations of ATP within the cell (ca. 1 mM) displayed a minimum at 0.01% P85. Overall,
this result is consistent with the earlier study, which demonstrated that low concentrations of
P85 (from about 0.001% to 0.1%) increased accumulation of a Pgp substrate, rhodamine 123,
in Pgp expressing cells (13). At higher concentrations (about 1%) the effect of P85 was reduced.
Most likely these effects relate to the aggregation behavior of P85 that forms micelles in
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aqueous solutions above the critical micellization concentration (CMC), 0.03% (36). Pluronic
molecules can also aggregate into two-dimensional micelles in lipid bilayers (37). While the
single chains of P85 are likely to affect Pgp resulting in inhibition of ATPase activity, the
interactions of Pgp with the micelles may “salvage” the ATPase activity. The situation,
however, may be very complex and involve multiple and different modes of interaction of P85
with Pgp, which is indirectly supported by difference in the copolymer concentrations acting
upon Vmax and Km.
It is unlikely that the effects P85 on the ATPase activity involve specific binding of this block
copolymer with the transport protein. This study demonstrates that P85 is not a substrate for
these proteins and does not bind to them like traditional low molecular mass chemosensitizers.
It is more probable, that P85 acts through: 1) changes of the membrane structure, which affect
the conformations of the transport proteins, and/or 2) sterically hinders the sites of binding of
the drugs with them. The conformational changes may involve the cytoplasmic ATP-binding
domains (NBDs) that are present in both Pgp and MRPs (4,5,38–40). It was shown previously
that kinetic parameters for binding and hydrolysis of ATP by Pgp depend on the state of the
lipid bilayer surrounding the protein. Specifically, the affinity of the protein with respect to
ATP diminishes as the fluidity of the membranes increases (upon heating) suggesting tight
relationship between NBDs function and the lipid membrane structure (41,42). However,
Tween-80 appears to have little effect on the critical Pgp conformations, and it is unclear
whether P85 would have such effect (43). Beside the NBDs the efflux proteins contain two
membrane-embedded domains, which span the cellular membrane and form high affinity drug-
binding sites (4,5,38,39). It was suggested that Pgp (44,45) extract the drugs from the inner
leaflet of the lipid bilayer and translocate them directly into the extracellular media. Thus, P85
chains embedded in the membrane may sterically hinder protein-drug interaction in the
appropriate binding sites. This mechanism is indirectly supported by the observation that P85
affects the Vmax and Km values for Vin in Pgp membranes under ATP-saturated conditions.
It is noteworthy, that P85 had substantially less effects on MRP1 and MRP2 ATPase activities
compared to the pronounced effects on Pgp. These differences were apparent for ATP as well
as the drug molecules. Overall, the ATPase inhibition potency of P85 increased in the row
MRP1 < MRP2 << Pgp. On the one hand, it cannot be excluded that the structure of MRPs is
more robust and less vulnerable to the conformational changes caused by P85 than the structure
of Pgp. On the other hand, although it was suggested that MRPs like the Pgp extract the drugs
from the lipid bilayer (5,39), the high affinity drug-binding sites of MRPs may be less accessible
for the hindrance by the block copolymer than similar sites of Pgp.
The effect of P85 on ATPase activity of the different transport proteins is consistent with the
reports that the sensitization effects of the block copolymer in resistant cells also increase in
the same order: MRP1 < MRP2 << Pgp (12,15). This reinforces the relationship between the
effects of Pluronics on different drug efflux transport systems and ATPase activities of the
transport proteins. It is likely that even under the conditions of ATP depletion induced by the
block copolymer the efflux proteins retain the ability to transport their substrates if the ATPase
function is not affected (14). In other words even if the concentration of ATP in the cells is
decreased several fold the amount of ATP available can be still sufficient to maintain the
function of the MRP transporters. However, in the case of Pgp there is a simultaneous ATP
depletion and strong inhibition of ATPase, which results in strong inhibition of this drug efflux
system.
Overall, addition of Pluronic block copolymer to the cells overexpressing Pgp and MRPs efflux
proteins reduces affinity and/or accessibility for the substrate-binding sites of the transporter.
However, the magnitude of P85 effects is considerably higher for Pgp than for MRP1 and
MRP2. This conclusion is in a good agreement with previous reports (15,17,46) showing
Batrakova et al. Page 7













significant inhibition of drug efflux transporters by nonionic surfactants in Pgp- and much less
in MRPs overexpressing cells. These data have provided insight into the mechanism by which
P85 affect the Pgp and MRPs efflux transport systems.
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Western blot analysis of the membranes overexpressing drug efflux transporters: Pgp (line 1),
MRP1 (line 2), and MRP2 (line 3). A total of 25 μg of protein was loaded onto 7.5%
polyacrylamide gels. Primary antibodies for Pgp (C219), MRP1 (MRPm6), and MRP2
(M2III-6) were used at dilutions of 1:100. The monoclonal antibodies to β-actin, anti-β-1-
chicken integrin were used at 1:200 dilution. Secondary antibody was used at a 1:1500 dilution.
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(A) Concentration-dependent effects of Mg2+ATP on Pgp ATPase activity of Pgp-expressing
membranes in P85-free (filled diamonds), 0.01% P85 (empty squares), 0.1% P85 (empty
triangles), and 1% P85 solutions (crosses). Incubation t = 20 min. Each point shows the mean
of triplicate experiments ± SD (B) Calculation of kinetic parameters Vmax and Km by double
reciprocal Lineweaverer-Burk plot for reaction dephosphorilation of Mg2+ATP by Pgp in P85-
free (filled diamonds), 0.01% P85 (empty squares), 0.1% P85 (empty triangles), and 1% P85
(crosses) solutions.
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Dose response of Vin-stimulated Pgp ATPase activity of Pgp overexpressing membranes in
P85-free (filled diamonds), 0.01% P85 (empty squares), and 0.1% P85 solution (empty
triangles). Incubation t = 20 min, [Mg2+ATP] = 4 mM. Each point shows the mean of triplicate
experiments ± SD.
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(A) Effects of Mg2+ATP on MRP1 ATPase activity of COR-L23/R membranes in P85-free
(filled diamonds) and 0.1% P85 solutions (empty triangles). Incubation t = 20 min. (B) Dose
response of Vin-stimulated MRP1 ATPase activity of COR-L23/R membranes in P85-free
(filled diamonds) and 0.1% P85 solution (empty triangles). Incubation t = 20 min, [Mg2+ATP]
= 4 mM. Each point shows the mean of triplicate experiments ± SD.
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(A) Effects of Mg2+ATP on MRP2 ATPase activity of MDCKII-MRP2 membranes in P85-
free (filled diamonds) and 0.1% P85 solutions (empty triangles). Incubation t = 20 min. (B)
Dose response of Vin-stimulated MRP2 ATPase activity of MDCKII-MRP2 membranes in
P85-free (filled diamonds) and 0.1% P85 solution (empty triangles). Incubation t = 20 min,
[Mg2+ATP] = 4 mM. Each point shows the mean of triplicate experiments ± SD.
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Time-dependent accumulation of 3H-P85 in MDCKII-MRP1 (triangles) and LLC-MDR1
(squares) monolayers using assay buffer (filled symbols), 10 μM indomethacin (filled
triangles), and 1 μM GF120918 (filled squares). Values represent the mean ± SD of four cell
monolayers.
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Table I
Effect of P85 on Kinetic Parameters of ATP-Pgp Interaction
Treatment
Vmax




Assay buffer 2.4 ± 0.36 0.4 ± 0.08 6
0.001% P85 2.4 ± 0.41 (NS) 0.7 ± 0.05* 3.4
0.01% P85 2.4 ± 0.22 (NS) 4 ± 0.9* 0.6
0.1% P85 1.1 ± 0.25* 0.9 ± 0.17* 1.2
1% P85 2.4 ± 0.33 (NS) 0.4 ± 0.07 (NS) 6
a
Statistical significance of P85 effects compared to the P85-free controls is shown in the brackets: NS, nonsignificant. Each parameter shows the mean
of triplicate experiments ± SD.
*
p < 0.05.






































































































































































































































































































































































































































































































































































































































































































































































































































































Pharm Res. Author manuscript; available in PMC 2009 May 5.
